Skip to main content
Top
Published in: International Journal of Hematology 6/2018

01-12-2018 | Case Report

C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies

Authors: Kateřina Staňo Kozubík, Lenka Radová, Michaela Pešová, Kamila Réblová, Jakub Trizuljak, Karla Plevová, Veronika Fiamoli, Jaromír Gumulec, Helena Urbánková, Tomáš Szotkowski, Jiří Mayer, Šárka Pospíšilová, Michael Doubek

Published in: International Journal of Hematology | Issue 6/2018

Login to get access

Abstract

Here we report a C-terminal RUNX1 mutation in a family with platelet disorder and predisposition to myeloid malignancies. We identified the mutation c.866delG:p.Gly289Aspfs*22 (NM_001754) (RUNX1 b-isoform NM_001001890; c.785delG:p.Gly262Aspfs*22) using exome sequencing of samples obtained from eight members of a single family. The mutation found in our pedigree is within exon eight and the transactivation domain of RUNX1. One of the affected individuals developed myelodysplastic syndrome (MDS), which progressed to acute myelogenous leukemia (AML). A search for the second hit which led to the development of MDS and later AML in this individual revealed the PHF6 gene variant (exon9:c.872G > A:p.G291E; NM_001015877), BCORL1 (exon3:c.1111A > C:p.T371P; NM_001184772) and BCOR gene variant (exon4:c.2076dupT:p.P693fs; NM_001123383), which appear to be very likely second hits participating in the progression to myeloid malignancy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schlegelberger B, Heller PG. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol. 2017;54(2):75–80.CrossRef Schlegelberger B, Heller PG. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol. 2017;54(2):75–80.CrossRef
2.
go back to reference Hayashi Y, Harada Y, Huang G, Harada H. Myeloid neoplasms with germ line RUNX1 mutation. Int J Hematol. 2017;106:183–8.CrossRef Hayashi Y, Harada Y, Huang G, Harada H. Myeloid neoplasms with germ line RUNX1 mutation. Int J Hematol. 2017;106:183–8.CrossRef
3.
go back to reference Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817–24.PubMed Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817–24.PubMed
4.
go back to reference Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166–75.CrossRef Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166–75.CrossRef
6.
go back to reference Shiba N, Hasegawa D, Park MJ, Murata C, Sato-Otsubo A, Ogawa C, et al. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML). Blood. 2012;119(11):2612–4.CrossRef Shiba N, Hasegawa D, Park MJ, Murata C, Sato-Otsubo A, Ogawa C, et al. CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML). Blood. 2012;119(11):2612–4.CrossRef
7.
go back to reference Bellissimo DC, Speck NA. RUNX1 mutations in inherited and sporadic leukemia. Front Cell Dev Biol. 2017;5:111.CrossRef Bellissimo DC, Speck NA. RUNX1 mutations in inherited and sporadic leukemia. Front Cell Dev Biol. 2017;5:111.CrossRef
8.
go back to reference Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25(1):130–4.CrossRef Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25(1):130–4.CrossRef
10.
go back to reference Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, et al. and BCORL1 mutations in myelodysplastic syndromes and related disorders. BCOR. 2013;122(18):3169–77. Blood. Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, et al. and BCORL1 mutations in myelodysplastic syndromes and related disorders. BCOR. 2013;122(18):3169–77. Blood.
11.
go back to reference Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathways mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.CrossRef Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathways mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.CrossRef
12.
go back to reference Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, et al. Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. Leukemia. 2016;30(11):2270–3.CrossRef Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, et al. Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. Leukemia. 2016;30(11):2270–3.CrossRef
15.
go back to reference Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29:1364–72.CrossRef Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29:1364–72.CrossRef
16.
go back to reference Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, et al. Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leuk Res Rep. 2015;4(1):24–7.PubMedPubMedCentral Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, et al. Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leuk Res Rep. 2015;4(1):24–7.PubMedPubMedCentral
17.
go back to reference Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, et al. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Ann Oncol. 2016;27:887–95.CrossRef Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, et al. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Ann Oncol. 2016;27:887–95.CrossRef
18.
go back to reference Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011;96:1536–42.CrossRef Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011;96:1536–42.CrossRef
19.
go back to reference Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M,et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBOJ. 2007;26:1163–75.CrossRef Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M,et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBOJ. 2007;26:1163–75.CrossRef
20.
go back to reference Ripperger T, Steinemann D, Gohring G, Finke J, Niemeyer CM, StrahmB,et al. A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia. 2009;23:1364–6.CrossRef Ripperger T, Steinemann D, Gohring G, Finke J, Niemeyer CM, StrahmB,et al. A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia. 2009;23:1364–6.CrossRef
21.
go back to reference Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–77.CrossRef Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–77.CrossRef
22.
go back to reference Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, et al. AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem. 2008;283(44):30045–56.CrossRef Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, et al. AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem. 2008;283(44):30045–56.CrossRef
23.
go back to reference Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126(22):2484–90.CrossRef Churpek JE, Pyrtel K, Kanchi KL, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126(22):2484–90.CrossRef
Metadata
Title
C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies
Authors
Kateřina Staňo Kozubík
Lenka Radová
Michaela Pešová
Kamila Réblová
Jakub Trizuljak
Karla Plevová
Veronika Fiamoli
Jaromír Gumulec
Helena Urbánková
Tomáš Szotkowski
Jiří Mayer
Šárka Pospíšilová
Michael Doubek
Publication date
01-12-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2514-3

Other articles of this Issue 6/2018

International Journal of Hematology 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine